Tumor priming enhances delivery and efficacy of nanomedicines

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 80-88

  Lu, Dan ^a,c   Wientjes, M Guillaume ^a,b   Lu, Ze ^c   Au, Jessie L S ^a,b,d  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Optimum Therapeutics LLC   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUORESCENT DYE; LIPOSOME; NANOPARTICLE; PACLITAXEL;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL DIAMETER; CANCER TISSUE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; HUMAN TISSUE; INTERSTITIUM; KINETICS; LIPOSOMAL DELIVERY; MALE; MOUSE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PERFUSION; PRIORITY JOURNAL; TISSUE PRESSURE; TOXICITY; TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; LIPOSOMES; MALE; MICE; MICE, NUDE; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; PACLITAXEL;

EID: 34250765337     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.121632     Document Type: Article

References (40)

1. Abe I, Hori K, Saito S, Tanda S, Li YL, and Suzuki M (1988) Increased intratumor concentration of fluorescein-isothiocyanate-labeled neocarzinostatin in rats under angiotensin-induced hypertension. Jpn J Cancer Res 79:874-879.
2. Au JL, Kalns J, Gan Y, and Wientjes MG (1997) Pharmacologic effects of taxol in human bladder tumors. Cancer Chemother Pharmacol 41:69-74.
3. Au JL, Li D, Gan Y, Gao X, Johnson AL, Johnston J, Millenbaugh NJ, Jang SH, Kuh HJ, Chen CT, et al. (1998) Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 58:2141-2148.
4. Baker AF and Dorr RT (2001) Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 27:221-233.
5. Briasoulis E, Pentheroudakis G, Karavasilis V, Tzamakou E, Rammou D, and Pavlidis N (2004) Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. Ann Oncol 15:1566-1573.
6. Brinckerhoff CE, Rutter JL, and Benbow U (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6:4823-4830.
7. Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF Jr, Wilson KS, Puchalski TA, Supko JG, et al. (2003) Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol 90:610-618.
8. Chang E, Chalikonda S, Friedl J, Xu H, Phan GQ, Marincola FM, Alexander HR, and Bartlett DL (2005) Targeting vaccinia to solid tumors with local hyperthermia. Hum Gene Ther 16:435-444.
9. Chen CT, Gan Y, Au JL, and Wientjes MG (1998) Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res 58:2777-2783.
10. Chin DL, Lum BL, and Sikic BI (2002) Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 779:259-269.
11. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
12. Davison AC and Hinkley DV (1997) Bootstrap Methods and Their Application, pp 136-190, Cambridge University Press, Cambridge, UK.
13. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324.
14. Eikenes L, Bruland OS, Brekken C, and Davies CL (2004) Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res 64:4768-4773.
15. Eikenes L, Tari M, Tufto I, Bruland OS, and de Lange DC (2005) Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer 93:81-88.
16. Elizondo FG and Sung C (1996) Effect of angiotensin II on immunotoxin uptake in tumor and normal tissue. Cancer Chemother Pharmacol 39:113-121.
17. Flessner MF, Choi J, Credit K, Deverkadra R, and Henderson K (2005) Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin Cancer Res 11:3117-3125.
18. Gabizon A, Shmeeda H, and Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436.
19. Gan Y, Wientjes MG, Lu J, and Au JL (1998) Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother Pharmacol 42:177-182.
20. Gan Y, Wientjes MG, Schuller DE, and Au JL (1996) Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 56:2086-2093.
21. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, and Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59:3776-3782.
22. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, and Stewart JS (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7:243-254.
23. Holden SA, Lan Y, Pardo AM, Wesolowski JS, and Gillies SD (2001) Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 7:2862-2869.
24. Hoshi M and Sato H (1995) Angiotensin II-induced hypertension chemotherapy (IHC) for advanced gastrointestinal, pancreatic and hepatobiliary carcinoma. Intern Med 34:298-299.
25. Jang SH, Wientjes MG, and Au JL (2001) Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 296:1035-1042.
26. Jang SH, Wientjes MG, Lu D, and Au JL (2003) Drug delivery and transport to solid tumors. Pharm Res 20:1337-1350.
27. Kong G, Braun RD, and Dewhirst MW (2000) Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 60:4440-4445.
28. Kovar JL, Johnson MA, Volcheck WM, Chen J, and Simpson MA (2006) Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol 169:1415-1426.
29. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, and Peters LJ (1995) Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 35:297-303.
30. Millenbaugh NJ, Gan Y, and Au JL (1998) Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors. Pharm Res 15:122-127.
31. Minotti G, Saponiero A, Licata S, Menna P, Calafiore AM, Teodori G, and Gianni L (2001) Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 7:1511-1515.
32. Ogawara K, Higaki K, and Kimura T (2002) Major determinants in hepatic disposition of polystyrene nanospheres: implication for rational design of particulate drug carriers. Crit Rev Ther Drug Carrier Syst 19:277-306.
33. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, and Donehower RC (1993) Taxol: pharmacology, metabolism, and clinical applications. Cancer Surv 17:283-304.
34. Suzuki M, Hori K, Abe I, Saito S, and Sato H (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 67:663-669.
35. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736.
36. Trotter MJ, Chaplin DJ, and Olive PL (1989) Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer 59:706-709.
37. Tsuchida Y and Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37:1-3.
38. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, et al. (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474-2484.
39. Yeh TK, Lu Z, Wientjes MG, and Au JL (2005) Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 22:867-874.
40. Yuan F, Leunig M, Huang SK, Berk DA, Papahakjopoulos D, and Jain RK (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356.